Eledon Q2 FY26 net loss widens to $31.6 million
ELDN•Q2 FY26 financial results
- Eledon Pharmaceuticals posted a wider Q2 2026 net loss of $31.6 million, or $0.27 per share, versus $11.2 million.
- R&D expense fell to $18.2 million from $20.3 million, while G&A edged up to $4.6 million from $4.5 million.
- Cash, cash equivalents and short-term investments slid to $88.8 million at June 30 from $133.3 million at Dec. 31.
- Net loss included a $9.6 million non-cash warrant fair-value loss versus a $12.3 million non-cash gain a year earlier.
Clinical development update
David-Alexandre C. Gros said a successful FDA end-of-Phase 2 meeting keeps a global Phase 3 kidney transplant trial on track for late 2026.
